[Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide].

Odin VI, Belikova TV, Pushkova ES, Barr NA

Advances in gerontology = Uspekhi gerontologii1 Jan 2004Cited by 1 (Europe PMC)

PMID15754961PepBankPUB-15754961

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone19

In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Delta sleep-inducing peptide (DSIP).

01HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, 60 days of Deltaran (a DSIP-containing drug) improved the SCAG score for impairment of recent memory (p=0.003).
In plain wordsIn 11 elderly people with diabetes, memory problems scored better after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseSCAG impairment of recent memory
Study
n = 11
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
After treatment were observed improvement of the parameters of quality of life on SCAG scale as the impairment of recent memory (p=0.003), mood depression (p=0.019), emotional lability (p=0.002) and anxiety (p=0.000).
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496101
02HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) improved the SCAG score for mood depression (p=0.019).
In plain wordsIn 11 elderly people with diabetes, low mood scored better after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseSCAG mood depression
Study
n = 11
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
After treatment were observed improvement of the parameters of quality of life on SCAG scale as the impairment of recent memory (p=0.003), mood depression (p=0.019), emotional lability (p=0.002) and anxiety (p=0.000).
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496102
03HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) improved the SCAG score for emotional lability (p=0.002).
In plain wordsIn 11 elderly people with diabetes, mood swings scored better after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseSCAG emotional lability
Study
n = 11
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
After treatment were observed improvement of the parameters of quality of life on SCAG scale as the impairment of recent memory (p=0.003), mood depression (p=0.019), emotional lability (p=0.002) and anxiety (p=0.000).
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496103
04HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) improved the SCAG score for anxiety (p=0.000).
In plain wordsIn 11 elderly people with diabetes, anxiety scored better after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseSCAG anxiety
Study
n = 11
Outcome group
Anxiety and mood · Mental health and mood
Source sentences
Summary
After treatment were observed improvement of the parameters of quality of life on SCAG scale as the impairment of recent memory (p=0.003), mood depression (p=0.019), emotional lability (p=0.002) and anxiety (p=0.000).
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496104
05HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) improved the quality of sleep (p=0.010).
In plain wordsIn 11 elderly people with diabetes, sleep quality improved after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
IncreaseQuality of sleep
Study
n = 11
Outcome group
Sleep · Sleep
Source sentences
Summary
Also were observed improvement of quality of sleep and felling between meals in treating patients (p=0.010).
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496105
06HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) improved the feeling between meals (p=0.010).
In plain wordsIn 11 elderly people with diabetes, the feeling between meals improved after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
IncreaseFeeling between meals
Study
n = 11
Outcome group
Quality of life · Whole body
Source sentences
Summary
Also were observed improvement of quality of sleep and felling between meals in treating patients (p=0.010).
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496106
07HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, the decrease of blood pressure with Deltaran (a DSIP-containing drug) was not significant.
In plain wordsIn 11 elderly people with diabetes, blood pressure did not change significantly with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
No significant changeBlood pressure
Study
n = 11
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
decrease of BP (ns)
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496107
08HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, the increase of ABI with Deltaran (a DSIP-containing drug) was not significant.
In plain wordsIn 11 elderly people with diabetes, the ankle-brachial index did not change significantly with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
No significant changeAnkle-brachial index (ABI)
Study
n = 11
Outcome group
Vascular function · Cardiovascular
Source sentences
Summary
increase of ABI (ns)
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496108
09HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) increased pallesthesia (p=0.017).
In plain wordsIn 11 elderly people with diabetes, vibration sense improved after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
IncreasePallesthesia (vibration sense)
Study
n = 11
Outcome group
Sensory perception · Nervous system and cognition
Source sentences
Summary
increase of pallestesia (p=0.017)
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496109
10HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) decreased the frequency of microalbuminuria (p=0.011).
In plain wordsIn 11 elderly people with diabetes, protein in urine was less frequent after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseFrequency of microalbuminuria (MAU)
Study
n = 11
Outcome group
Kidney function · Kidney and urinary
Source sentences
Summary
decrease of MAU frequency (p=0.011)
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496110
11HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) decreased glycaemia levels after load (p=0.033).
In plain wordsIn 11 elderly people with diabetes, blood sugar after a carbohydrate breakfast was lower after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseGlycaemia after carbohydrate load
Study
n = 11
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
decrease of glycaemia levels after load (p=0.033)
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496111
12HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) decreased the basal blood level of growth hormone (p=0.034).
In plain wordsIn 11 elderly people with diabetes, resting growth hormone was lower after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseBasal growth hormone level
Study
n = 11
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
decrease of basal and reactive levels in blood of growth hormone (p=0.034 and p=0.005 accord.)
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496112
13HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, Deltaran (a DSIP-containing drug) decreased the reactive blood level of growth hormone (p=0.005).
In plain wordsIn 11 elderly people with diabetes, growth hormone after the breakfast test was lower after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseReactive growth hormone level
Study
n = 11
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
decrease of basal and reactive levels in blood of growth hormone (p=0.034 and p=0.005 accord.)
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496113
14HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, the decrease of insulin level with Deltaran (a DSIP-containing drug) was not significant.
In plain wordsIn 11 elderly people with diabetes, insulin levels did not change significantly with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
No significant changeInsulin level
Study
n = 11
Outcome group
Glycemic control · Endocrine and hormones
Source sentences
Summary
And also after treatment were observed decrease of basal and reactive levels in blood of growth hormone (p=0.034 and p=0.005 accord.), insulin (ns), cortisol (ns) and on the contrary increase of dehydroepiandrosterone sulfate levels (ns).
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496114
15HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, the decrease of cortisol level with Deltaran (a DSIP-containing drug) was not significant.
In plain wordsIn 11 elderly people with diabetes, cortisol did not change significantly with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
No significant changeCortisol level
Study
n = 11
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
And also after treatment were observed decrease of basal and reactive levels in blood of growth hormone (p=0.034 and p=0.005 accord.), insulin (ns), cortisol (ns) and on the contrary increase of dehydroepiandrosterone sulfate levels (ns).
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496115
16HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In 11 elderly diabetic patients, the increase of dehydroepiandrosterone sulfate level with Deltaran (a DSIP-containing drug) was not significant.
In plain wordsIn 11 elderly people with diabetes, dehydroepiandrosterone sulfate did not change significantly with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
No significant changeDehydroepiandrosterone sulfate level
Study
n = 11
Outcome group
Stress hormones · Endocrine and hormones
Source sentences
Summary
And also after treatment were observed decrease of basal and reactive levels in blood of growth hormone (p=0.034 and p=0.005 accord.), insulin (ns), cortisol (ns) and on the contrary increase of dehydroepiandrosterone sulfate levels (ns).
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496116
17HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In elderly diabetic patients who received only a diabetic diet, insulin resistance decreased with Deltaran (a DSIP-containing drug).
In plain wordsIn elderly people with diabetes on diet only, insulin resistance fell after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseInsulin resistance in patients on diabetic diet only
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Main positive change observed in patients received only diabetic diet, where was a decrease of insulin resistance and in patients with latent autoimmune diabetes (type LADA), where was a increase insulin secretion and decrease of daily dose of insulin requiring.
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496117
18HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In elderly patients with latent autoimmune diabetes (LADA), insulin secretion increased with Deltaran (a DSIP-containing drug).
In plain wordsIn elderly people with latent autoimmune diabetes, insulin secretion rose after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
IncreaseInsulin secretion in patients with LADA
Study
n: not reported in source
Outcome group
Glycemic control · Endocrine and hormones
Source sentences
Summary
Main positive change observed in patients received only diabetic diet, where was a decrease of insulin resistance and in patients with latent autoimmune diabetes (type LADA), where was a increase insulin secretion and decrease of daily dose of insulin requiring.
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496118
19HumanNot a test of Delta sleep-inducing peptide (DSIP) aloneNon-randomized trialEfficacy outcome
In elderly patients with latent autoimmune diabetes (LADA), the daily insulin dose needed decreased with Deltaran (a DSIP-containing drug).
In plain wordsIn elderly people with latent autoimmune diabetes, the daily insulin dose needed fell after treatment with the DSIP-containing drug Deltaran.
Peptide
Delta sleep-inducing peptide (DSIP)
Outcome
DecreaseDaily insulin dose in patients with LADA
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Main positive change observed in patients received only diabetic diet, where was a decrease of insulin resistance and in patients with latent autoimmune diabetes (type LADA), where was a increase insulin secretion and decrease of daily dose of insulin requiring.
1 context sentence(design, population, supporting numbers)
Summary · context
As the pilot study we examined 11 elderly diabetic patients (mean age 66.3 yr, BMI--28.5 kg/m2, duration of diabetes 12.5 yr). All patients receive 20 doses of DSIP-containing drug "Deltaran" daily. Tests was before and after 60 days after beginning treatment.
In this study, Delta sleep-inducing peptide (DSIP) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Delta sleep-inducing peptide (DSIP).
Report a problemFND-1575496119

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 17:28 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.